STOK Stock Forecast & Price Target

Stoke Therapeutics Inc demonstrates a strong potential for revenue growth driven by the promising efficacy of its lead candidate, zorevunersen, which has shown durable improvements in key endpoints over a two-year period. The company’s approach to target haploinsufficiency diseases using its proprietary TANGO method positions it favorably within the biotechnology sector, highlighting its potential for differentiation from standard of care treatments and enhancing its commercial viability. Additionally, positive data releases and increased confidence in the drug's prospects for market approval contribute to an optimistic long-term financial outlook, with projections suggesting significant revenue uptake upon launch.

Stoke Therapeutics Inc. has been experiencing significant financial challenges, as evidenced by a net loss of $38.3 million and a net operating loss of $43.1 million reported in the third quarter of 2025. The company's dependence on the successful commercial execution of its first medicine, zorevunersen, in a competitive landscape for Dravet syndrome therapies exposes it to heightened risks, including regulatory uncertainty and the potential for negative clinical outcomes. The biotechnology firm also faces the difficulties associated with navigating increasingly complex and price-sensitive markets, which could adversely affect its financial outlook if it fails to meet market expectations.